Suppr超能文献

一名复发的早期T细胞前体急性淋巴细胞白血病患者中,由获得性单亲二体导致的纯合JAK3 V674A突变的鉴定。

Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.

作者信息

Kawashima-Goto Sachiko, Imamura Toshihiko, Seki Masafumi, Kato Motohiro, Yoshida Kenichi, Sugimoto Atsuya, Kaneda Daisuke, Fujiki Atsushi, Miyachi Mitsuru, Nakatani Takuya, Osone Shinya, Ishida Hiroyuki, Taki Tomohiko, Takita Junko, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Miyano Satoru, Ogawa Seishi, Hosoi Hajime

机构信息

Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kajii-cho Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.

出版信息

Int J Hematol. 2015 Apr;101(4):411-6. doi: 10.1007/s12185-014-1711-y. Epub 2014 Nov 28.

Abstract

Investigation of genetic alterations associated with relapse in acute lymphoblastic leukemia (ALL) may help to identify druggable targets for specific therapies. Early T-cell precursor ALL (ETP-ALL) is a subtype of T-ALL with poor prognosis. Although the genetic landscape of ETP-ALL has been determined, genetic alterations related to the relapse of ETP-ALL have not been fully investigated. Here, we report the first patient with relapsed pediatric ETP-ALL to exhibit a homozygous JAK3 activating mutation, V674A, caused by acquired uniparental disomy (UPD). Single nucleotide polymorphism array analysis revealed acquired UPD (aUPD) at the 19p13.3-p12 locus only in leukemic cells at relapse. Sanger sequence of the JAK3 gene, which was located at 19p13.1 and frequently mutated in ETP-ALL, was performed in paired leukemic samples to determine homozygous JAK3 V674A mutation only in relapsed leukemic cells. In contrast, leukemic cells at initial diagnosis harbored hemizygous JAK3 V674A mutation. Further, whole-exome sequencing revealed mutations in 18 genes only in relapsed samples, although none of these was recurrent in T-ALL. These findings suggest that aUPD at 19p13.1 is partly associated with relapse in this patient. Pharmacological inhibition of JAK3 may be therapeutic in such cases.

摘要

对急性淋巴细胞白血病(ALL)复发相关基因改变的研究可能有助于确定特定疗法的可药物靶向。早期T细胞前体ALL(ETP-ALL)是预后较差的T-ALL亚型。尽管ETP-ALL的基因图谱已确定,但与ETP-ALL复发相关的基因改变尚未得到充分研究。在此,我们报告首例复发的儿童ETP-ALL患者,其因获得性单亲二体性(UPD)而出现纯合JAK3激活突变V674A。单核苷酸多态性阵列分析显示,仅在复发时的白血病细胞中19p13.3-p12位点存在获得性UPD(aUPD)。对位于19p13.1且在ETP-ALL中频繁突变的JAK3基因进行Sanger测序,在配对的白血病样本中进行检测,结果显示仅在复发的白血病细胞中存在纯合JAK3 V674A突变。相比之下,初诊时的白血病细胞携带半合子JAK3 V674A突变。此外,全外显子测序显示仅在复发样本中有18个基因发生突变,尽管这些基因在T-ALL中均未反复出现。这些发现表明,19p13.1处的aUPD与此例患者的复发部分相关。在这类病例中,JAK3的药理抑制可能具有治疗作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验